Bio-Thera Claims A World First With Chinese Tocilizumab Approval
Actemra/RoActemra Gets NMPA Nod; Offers Option For COVID-19 Treatment
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.
You may also be interested in...
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”